17 citations
,
January 2013 in “Indian Journal of Pharmacology”
This case report highlights an interest in exploring the relationship between serum levels of sodium valproate and hairloss, though no case reports currently establish this link.
This case report details a 54-year-old woman with metastatic non-small-cell lung cancer who experienced severe hairloss and exanthematous drug eruption, potentially linked to erlotinib hypersensitivity.
5 citations
,
February 2013 in “Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology”
This case report observed that an adolescent female experienced hairloss with fluoxetine and sertraline, which resolved with venlafaxine, suggesting potential alopecia as an adverse reaction to these SSRIs.
This review discusses the scalp microinfusion MMP® technique for hairloss treatment and reports no new results; it emphasizes the need for more standardized studies.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hairloss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
Minoxidil increases hair count despite high prolactin being linked to hairloss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.
An arthritis drug, Rinvoq, restores hair in some alopecia areata patients but is not effective for androgenetic alopecia. It is used for autoimmune-related skin disorders, but its high cost and lack of insurance coverage are issues.
Minoxidil alone is often insufficient for treating hairloss because it doesn't address the DHT-related cause. Combining it with finasteride, a DHT blocker, is generally more effective.
What is tofacitinib, and why is it discussed in relation to autoimmune-relatedhairloss such as alopecia areata?Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
What side effects or limitations have been reported with Setipiprant use in hairloss research?In the one published hair-loss trial (DuBois 2021, 169 men, 24 weeks), setipiprant produced no significant hair regrowth over placebo. Treatment-related side effects — mostly mild headaches, stomach upset and fatigue — were reported in about a quarter of the setipiprant group versus just over twelve percent on placebo, and no serious events were attributed to the drug. It is an unapproved, experimental compound with no long-term safety data.